Phase 2
Completed N=44
Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)
Neuromuscular Blockade
Source: ClinicalTrials.gov NCT03532178 ↗
Enrolled (actual)
44
Serious AEs
0.0%
Results posted
Sep 2023
Primary outcomePrimary: Recovery Time of T1 to 90% Baseline — 6.79; 10.97 minutes
Summary
The investigators propose to compare the recovery of neuromuscular blockade from rocuronium reversal by sugammadex to succinylcholine in ECT.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Recovery Time of T1 to 90% Baseline |
6.79; 10.97 | — |
| SECONDARY Number of Participants With Treatment or Emergent Adverse Events of the Drugs |
1; 3; 1; 2; 7; 9 | — |
Eligibility Criteria
Inclusion Criteria
- Eligible and scheduled for ECT
- Has the capacity to consent for the study
Exclusion Criteria
- Any acute major organ failure in the last 30 days
- Any known or suspected neuromuscular disorders
- Any history of allergic reaction or intolerance to sugammadex, rocuronium, or succinylcholine
- Any conditions with severe renal impairment, including those requiring dialysis
- Anyone currently taking lithium
- Anyone currently taking hormonal contraceptives
- Anyone taking anti-coagulants, including vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran
Data sourced from ClinicalTrials.gov (NCT03532178). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.